Estrella Immunopharma, Inc. (ESLAW)
ESLAW Stock Price Chart
Explore Estrella Immunopharma, Inc. interactive price chart. Choose custom timeframes to analyze ESLAW price movements and trends.
ESLAW Company Profile
Discover essential business fundamentals and corporate details for Estrella Immunopharma, Inc. (ESLAW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2023
Employees
3.00
Website
https://www.estrellabio.comCEO
Cheng Liu
Description
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.
ESLAW Financial Timeline
Browse a chronological timeline of Estrella Immunopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
ESLAW Stock Performance
Access detailed ESLAW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
